Selected research
Market Structure
Global Meningococcal Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Meningococcal Disease Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.
The US & Canada market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Meningococcal Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Meningococcal Disease Drugs include Yiling Pharmaceutical, SSY Group Limited, Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Lukang Pharmaceutical Co.,Ltd., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and North China Pharmaceutical Company Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Meningococcal Disease Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Meningococcal Disease Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Meningococcal Disease Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Meningococcal Disease Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Meningococcal Disease Drugs Segment by Company
Yiling Pharmaceutical
SSY Group Limited
Apeloa Pharmaceutical Co.,Ltd.
Novartis
Merck Sharp & Dohme
Lukang Pharmaceutical Co.,Ltd.
Shandong Jincheng Pharmaceutical Group Co.,ltd.
Pfizer
North China Pharmaceutical Company Ltd.
Hebei Hejia Pharmaceutical Technology Group Co., Ltd
Harbin Pharmaceutical Group Co.,Ltd.
GlaxoSmithKline
Baiyunshan Pharmaceutical
Sanofi Pasteur
Meningococcal Disease Drugs Segment by Type
Injectable
Oral
Meningococcal Disease Drugs Segment by Application
Hospitals
Drugstores
Others
Meningococcal Disease Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Meningococcal Disease Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Meningococcal Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Meningococcal Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Meningococcal Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Injectable
- Oral
Applications
- Hospitals
- Drugstores
- Others
Companies covered
- Yiling Pharmaceutical
- SSY Group Limited
- Apeloa Pharmaceutical Co.,Ltd.
- Novartis
- Merck Sharp & Dohme
- Lukang Pharmaceutical Co.,Ltd.
- Shandong Jincheng Pharmaceutical Group Co.,ltd.
- Pfizer
- North China Pharmaceutical Company Ltd.
- Hebei Hejia Pharmaceutical Technology Group Co., Ltd
- Harbin Pharmaceutical Group Co.,Ltd.
- GlaxoSmithKline
- Baiyunshan Pharmaceutical
- Sanofi Pasteur
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Meningococcal Disease Drugs Market Size, 2021 VS 2025 VS 2032
- 1.3 Global Meningococcal Disease Drugs Market Size Estimates and Forecasts (2021-2032)
- 1.4 Global Meningococcal Disease Drugs Sales Estimates and Forecasts (2021-2032)
- 1.5 Global Meningococcal Disease Drugs Market Average Price (2021-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
2 Global Meningococcal Disease Drugs Market Dynamics
- 2.1 Meningococcal Disease Drugs Industry Trends
- 2.2 Meningococcal Disease Drugs Industry Drivers
- 2.3 Meningococcal Disease Drugs Industry Opportunities and Challenges
- 2.4 Meningococcal Disease Drugs Industry Restraints
3 Meningococcal Disease Drugs Market by Manufacturers
- 3.1 Global Meningococcal Disease Drugs Revenue by Manufacturers (2021-2026)
- 3.2 Global Meningococcal Disease Drugs Sales by Manufacturers (2021-2026)
- 3.3 Global Meningococcal Disease Drugs Average Sales Price by Manufacturers (2021-2026)
- 3.4 Global Meningococcal Disease Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
- 3.5 Global Meningococcal Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Meningococcal Disease Drugs Manufacturers, Product Type & Application
- 3.7 Global Meningococcal Disease Drugs Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Meningococcal Disease Drugs Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Meningococcal Disease Drugs Players Market Share by Revenue in 2025
- 3.8.3 2025 Meningococcal Disease Drugs Tier 1, Tier 2, and Tier 3
4 Meningococcal Disease Drugs Market by Type
- 4.1 Meningococcal Disease Drugs Type Introduction
- 4.1.1 Injectable
- 4.1.2 Oral
- 4.2 Global Meningococcal Disease Drugs Sales by Type
- 4.2.1 Global Meningococcal Disease Drugs Sales by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Meningococcal Disease Drugs Sales by Type (2021-2032)
- 4.2.3 Global Meningococcal Disease Drugs Sales Market Share by Type (2021-2032)
- 4.3 Global Meningococcal Disease Drugs Revenue by Type
- 4.3.1 Global Meningococcal Disease Drugs Revenue by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Meningococcal Disease Drugs Revenue by Type (2021-2032)
- 4.3.3 Global Meningococcal Disease Drugs Revenue Market Share by Type (2021-2032)
5 Meningococcal Disease Drugs Market by Application
- 5.1 Meningococcal Disease Drugs Application Introduction
- 5.1.1 Hospitals
- 5.1.2 Drugstores
- 5.1.3 Others
- 5.2 Global Meningococcal Disease Drugs Sales by Application
- 5.2.1 Global Meningococcal Disease Drugs Sales by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Meningococcal Disease Drugs Sales by Application (2021-2032)
- 5.2.3 Global Meningococcal Disease Drugs Sales Market Share by Application (2021-2032)
- 5.3 Global Meningococcal Disease Drugs Revenue by Application
- 5.3.1 Global Meningococcal Disease Drugs Revenue by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Meningococcal Disease Drugs Revenue by Application (2021-2032)
- 5.3.3 Global Meningococcal Disease Drugs Revenue Market Share by Application (2021-2032)
6 Global Meningococcal Disease Drugs Sales by Region
- 6.1 Global Meningococcal Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Meningococcal Disease Drugs Sales by Region (2021-2032)
- 6.2.1 Global Meningococcal Disease Drugs Sales by Region (2021-2026)
- 6.2.2 Global Meningococcal Disease Drugs Sales Forecasted by Region (2027-2032)
- 6.3 North America
- 6.3.1 North America Meningococcal Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.3.2 North America Meningococcal Disease Drugs Sales by Country (2021-2032)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Meningococcal Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.4.2 Europe Meningococcal Disease Drugs Sales by Country (2021-2032)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Meningococcal Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.5.2 Asia Pacific Meningococcal Disease Drugs Sales by Country (2021-2032)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Meningococcal Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
- 6.6.2 South America, Middle East and Africa Meningococcal Disease Drugs Sales by Country (2021-2032)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
7 Global Meningococcal Disease Drugs Revenue by Region
- 7.1 Global Meningococcal Disease Drugs Revenue by Region
- 7.1.1 Global Meningococcal Disease Drugs Revenue by Region: 2021 VS 2025 VS 2032
- 7.1.2 Global Meningococcal Disease Drugs Revenue by Region (2021-2026)
- 7.1.3 Global Meningococcal Disease Drugs Revenue by Region (2027-2032)
- 7.1.4 Global Meningococcal Disease Drugs Revenue Market Share by Region (2021-2032)
- 7.2 North America
- 7.2.1 North America Meningococcal Disease Drugs Revenue (2021-2032)
- 7.2.2 North America Meningococcal Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.3 Europe
- 7.3.1 Europe Meningococcal Disease Drugs Revenue (2021-2032)
- 7.3.2 Europe Meningococcal Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Meningococcal Disease Drugs Revenue (2021-2032)
- 7.4.2 Asia-Pacific Meningococcal Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Meningococcal Disease Drugs Revenue (2021-2032)
- 7.5.2 South America, Middle East and Africa Meningococcal Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
- 8.1 Yiling Pharmaceutical
- 8.1.1 Yiling Pharmaceutical Company Information
- 8.1.2 Yiling Pharmaceutical Business Overview
- 8.1.3 Yiling Pharmaceutical Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.1.4 Yiling Pharmaceutical Meningococcal Disease Drugs Product Portfolio
- 8.1.5 Yiling Pharmaceutical Recent Developments
- 8.2 SSY Group Limited
- 8.2.1 SSY Group Limited Company Information
- 8.2.2 SSY Group Limited Business Overview
- 8.2.3 SSY Group Limited Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.2.4 SSY Group Limited Meningococcal Disease Drugs Product Portfolio
- 8.2.5 SSY Group Limited Recent Developments
- 8.3 Apeloa Pharmaceutical Co.,Ltd.
- 8.3.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
- 8.3.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
- 8.3.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.3.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
- 8.3.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
- 8.4 Novartis
- 8.4.1 Novartis Company Information
- 8.4.2 Novartis Business Overview
- 8.4.3 Novartis Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.4.4 Novartis Meningococcal Disease Drugs Product Portfolio
- 8.4.5 Novartis Recent Developments
- 8.5 Merck Sharp & Dohme
- 8.5.1 Merck Sharp & Dohme Company Information
- 8.5.2 Merck Sharp & Dohme Business Overview
- 8.5.3 Merck Sharp & Dohme Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.5.4 Merck Sharp & Dohme Meningococcal Disease Drugs Product Portfolio
- 8.5.5 Merck Sharp & Dohme Recent Developments
- 8.6 Lukang Pharmaceutical Co.,Ltd.
- 8.6.1 Lukang Pharmaceutical Co.,Ltd. Company Information
- 8.6.2 Lukang Pharmaceutical Co.,Ltd. Business Overview
- 8.6.3 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.6.4 Lukang Pharmaceutical Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
- 8.6.5 Lukang Pharmaceutical Co.,Ltd. Recent Developments
- 8.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
- 8.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
- 8.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
- 8.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Drugs Product Portfolio
- 8.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
- 8.8 Pfizer
- 8.8.1 Pfizer Company Information
- 8.8.2 Pfizer Business Overview
- 8.8.3 Pfizer Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.8.4 Pfizer Meningococcal Disease Drugs Product Portfolio
- 8.8.5 Pfizer Recent Developments
- 8.9 North China Pharmaceutical Company Ltd.
- 8.9.1 North China Pharmaceutical Company Ltd. Company Information
- 8.9.2 North China Pharmaceutical Company Ltd. Business Overview
- 8.9.3 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.9.4 North China Pharmaceutical Company Ltd. Meningococcal Disease Drugs Product Portfolio
- 8.9.5 North China Pharmaceutical Company Ltd. Recent Developments
- 8.10 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
- 8.10.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
- 8.10.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
- 8.10.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.10.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Drugs Product Portfolio
- 8.10.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
- 8.11 Harbin Pharmaceutical Group Co.,Ltd.
- 8.11.1 Harbin Pharmaceutical Group Co.,Ltd. Company Information
- 8.11.2 Harbin Pharmaceutical Group Co.,Ltd. Business Overview
- 8.11.3 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.11.4 Harbin Pharmaceutical Group Co.,Ltd. Meningococcal Disease Drugs Product Portfolio
- 8.11.5 Harbin Pharmaceutical Group Co.,Ltd. Recent Developments
- 8.12 GlaxoSmithKline
- 8.12.1 GlaxoSmithKline Company Information
- 8.12.2 GlaxoSmithKline Business Overview
- 8.12.3 GlaxoSmithKline Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.12.4 GlaxoSmithKline Meningococcal Disease Drugs Product Portfolio
- 8.12.5 GlaxoSmithKline Recent Developments
- 8.13 Baiyunshan Pharmaceutical
- 8.13.1 Baiyunshan Pharmaceutical Company Information
- 8.13.2 Baiyunshan Pharmaceutical Business Overview
- 8.13.3 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.13.4 Baiyunshan Pharmaceutical Meningococcal Disease Drugs Product Portfolio
- 8.13.5 Baiyunshan Pharmaceutical Recent Developments
- 8.14 Sanofi Pasteur
- 8.14.1 Sanofi Pasteur Company Information
- 8.14.2 Sanofi Pasteur Business Overview
- 8.14.3 Sanofi Pasteur Meningococcal Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
- 8.14.4 Sanofi Pasteur Meningococcal Disease Drugs Product Portfolio
- 8.14.5 Sanofi Pasteur Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Meningococcal Disease Drugs Value Chain Analysis
- 9.1.1 Meningococcal Disease Drugs Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Meningococcal Disease Drugs Production Mode & Process
- 9.2 Meningococcal Disease Drugs Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Meningococcal Disease Drugs Distributors
- 9.2.3 Meningococcal Disease Drugs Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst